Table 2.
Clinicopathological characteristics of included EC patients in the primary and validation groups
| Clinpathologic characteristics | Primary group (n=158) | Validation group 1 (n=78) | Validation group 2 (n=51) | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|||||||
| Non-FPT (128) | FPT (30) | P value | Non-FPT (67) | FPT (11) | P value | Non-FPT (40) | FPT (11) | P value | |
| Age (years) | 42.7±5.8 | 41.8±6.7 | 0.05 | 42.9±5.1 | 39.8±8.8 | 0.08 | 43.4±6.8 | 40.5±6.7 | 0.43 |
| CA125 (U/ml) | 31.1±41.8 | 27.7±23.3 | 0.40 | 25.3±22.8 | 25.8±19.2 | 0.41 | 29.1±35.2 | 17.0±12.7 | 0.45 |
| Tumor size (mm) | 18.4±7.1 | 14.8±5.6 | 0.51 | 17.2±5.7 | 14.8±4.3 | 0.45 | 18.1±7.7 | 14.2±4.6 | 0.43 |
| ER (-/+) | 49/79 | 9/21 | 0.53 | 28/39 | 8/3 | 0.10 | 36/4 | 6/5 | 0.02 |
| PR (-/+) | 47/81 | 9/21 | 0.53 | 27/40 | 8/3 | 0.06 | 24/16 | 6/5 | 0.74 |
| p53 (-/+) | 69/59 | 17/13 | 0.84 | 37/30 | 10/1 | 0.04 | 32/8 | 6/5 | 0.12 |
| CSI (-/+) | 106/22 | 30/0 | 0.01 | 59/8 | 11/0 | 0.59 | 10/30 | 11/0 | 0.09 |
| EM (-/+) | 114/14 | 30/0 | 0.07 | 64/3 | 11/0 | 1.00 | 2/38 | 11/0 | 1.00 |
| MI (non-MI/MI) | 1/127 | 30/0 | <0.001 | 1/66 | 11/0 | <0.001 | 4/36 | 11/0 | <0.001 |
| RMI (non-MI/MI) | 50/78 | 18/12 | 0.02 | 37/30 | 7/4 | 0.62 | 12/28 | 11/0 | 0.28 |
| RCSI (-/+) | 109/19 | 29/1 | 0.13 | 61/6 | 10/1 | 1.00 | 7/33 | 11/0 | 0.32 |
| REM (-/+) | 105/23 | 26/4 | 0.79 | 58/9 | 9/2 | 0.65 | 2/38 | 11/0 | 1.00 |
| TGS (AH/G1/G2/G3) | 0/86/34/8 | 3/27/0/0 | <0.001 | 0/50/12/5 | 1/10/0/0 | 0.03 | 0/25/9/6 | 0/11/0/0 | 0.54 |
| TGC (AH/G1/G2/G3) | 6/96/10/16 | 3/27/0/0 | 0.09 | 0/49/8/10 | 1/10/0/0 | 0.05 | 0/23/12/5 | 1/10/0/0 | 0.02 |
| FIGO (IA/IB/II-IV) | 90/6/32 | 30/0/0 | 0.07 | 53/3/11 | 11/0/0/0 | 0.73 | 30/1/9 | 11/0/0 | 0.18 |
| Radscore | 0.1±0.2 | 0.4±0.2 | 0.51 | 0.1±0.1 | 0.2±0.1 | 0.04 | 0.1±0.2 | 0.6±0.3 | 0.43 |
AH, atypical hyperplasia; CA125, cancer antigen 125; CSI, cervical stromal invasion; DMI, deep myometrial invasion; EAC, endometrioid adenocarcinoma; EM, extrauterine metastasis; ER, estrogen receptor; FIGO, International Federation of Obstetrics and Gynecology; FPT, fertility-preserving treatment; LNM, lymph node metastasis; MI, myometrial invasion; OM, ovarian metastases; PR, progesterone receptor; RCSI, radiologist’s assessment of cervical stromal invasion; REM, radiologist’s assessment of extrauterine metastasis; RMI, radiologist’s assessment of myometrial invasion; TGC, tumor grade in curettage; TGS, tumor grade in surgical pathology.